A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma

External beam radiation therapy (XRT) with concomitant temozolomide and 6 cycles of adjuvant temozolomide (5/28-day schedule) improves survival in patients with newly diagnosed glioblastoma compared with XRT alone. Studies suggest that dose-dense temozolomide schedules and addition of cytostatic age...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilbert, Mark R., Gonzalez, Javier, Hunter, Kathy, Hess, Kenneth, Giglio, Pierre, Chang, Eric, Puduvalli, Vinay, Groves, Morris D., Colman, Howard, Conrad, Charles, Levin, Victor, Woo, Shaio, Mahajan, Anita, de Groot, John, Yung, W.K. Alfred
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098026/
https://www.ncbi.nlm.nih.gov/pubmed/20729242
http://dx.doi.org/10.1093/neuonc/noq100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098026/
https://www.ncbi.nlm.nih.gov/pubmed/20729242
http://dx.doi.org/10.1093/neuonc/noq100

Ejemplares similares